Teva Pharma Industries Ltd ADR
$ 31.21
-0.41%
31 Dec - close price
- Market Cap 35,806,687,000 USD
- Current Price $ 31.21
- High / Low $ 31.43 / 31.15
- Stock P/E 51.16
- Book Value 6.32
- EPS 0.61
- Next Earning Report 2026-01-28
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.10 %
- 52 Week High 31.99
- 52 Week Low 12.47
About
Teva Pharmaceutical Industries Limited (Ticker: TEVA) is a prominent global pharmaceutical company based in Petach Tikva, Israel, renowned for its extensive portfolio of generic and specialty pharmaceuticals, as well as biopharmaceuticals. With a robust presence in North America and Europe, Teva operates across various therapeutic areas, establishing itself as a key player within the competitive pharmaceutical sector. The company is committed to innovation and enhancing healthcare accessibility, leveraging its scientific expertise and vast market reach to deliver impactful health solutions for patients around the globe.
Analyst Target Price
$33.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-07-30 | 2025-05-07 | 2025-01-29 | 2024-11-06 | 2024-07-31 | 2024-05-08 | 2024-01-31 | 2023-11-08 | 2023-08-02 | 2023-05-10 | 2023-02-08 |
| Reported EPS | 0.78 | 0.66 | 0.52 | 0.71 | -0.39 | 0.61 | 0.48 | 1 | 0.6 | 0.56 | 0.4 | 0.71 |
| Estimated EPS | 0.67 | 0.62 | 0.46 | 0.7 | 0.66 | 0.55 | 0.51 | 0.77 | 0.61 | 0.53 | 0.56 | 0.71 |
| Surprise | 0.11 | 0.04 | 0.06 | 0.01 | -1.05 | 0.06 | -0.03 | 0.23 | -0.01 | 0.03 | -0.16 | 0 |
| Surprise Percentage | 16.4179% | 6.4516% | 13.0435% | 1.4286% | -159.0909% | 10.9091% | -5.8824% | 29.8701% | -1.6393% | 5.6604% | -28.5714% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-01-28 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.63 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None | None | None | None | None |
| Amount | $0.085 | $0.07225 | $0.289 | $0.289 | $0.289 | $0.289 | $0.289 | $0.289 | $0.289 | $0.289 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TEVA
2026-01-01 15:09:13
New options for Teva Pharmaceutical Industries (TEVA) with a February 2026 expiration are now available. Analysts identified a put contract at a $29.00 strike price and a call contract at a $31.50 strike price that offer potential investment opportunities through selling puts or covered calls, respectively, with associated premiums and annualized returns. The article details the potential returns and risks for each option, considering current market prices and implied volatilities.
2025-12-30 12:08:48
Oak Harvest Investment Services has acquired 50,000 shares in Teva Pharmaceutical Industries (NYSE:TEVA), valued at approximately $1.01 million, according to its latest SEC filing. This acquisition comes as company insiders have been net sellers, disposing of 622,060 shares worth $17.08 million in the past 90 days. Analysts maintain a "Buy" consensus rating for TEVA with an average target price of $32.88, while some firms have recently raised their price targets.
2025-12-30 12:08:48
The global peptide therapeutics market is projected to reach USD 78,898.8 million by 2032, growing from USD 50,439.4 million in 2025 at a CAGR of 6.6%. This growth is attributed to rising industry demand, expanding applications, and ongoing technological advancements. The report provides a comprehensive analysis of market size, revenue trends, key growth factors, competitive landscape, and regional assessments, offering actionable insights for strategic decision-making.
2025-12-30 08:08:48
S&P Global Ratings upgraded Teva Pharmaceutical Industries Ltd.'s long-term issuer credit rating, and Moody's Ratings Agency revised its outlook to positive, citing the company's progress towards investment-grade status, improved adjusted leverage, and a return to revenue growth. Piper Sandler and Goldman Sachs subsequently raised their price targets for Teva, with Piper Sandler noting a shift towards a more appropriate peer group of larger cap biopharma companies. These upgrades and positive analyst revisions reflect growing confidence in Teva's operational and financial recovery.
2025-12-29 07:09:10
The Avascular Necrosis Market is projected for substantial growth from 2025 to 2032, driven by increasing industry demand and technological advancements. A new report by Coherent Market Insights offers a detailed analysis of market size, revenue trends, key growth factors, and competitive landscape, providing actionable insights for stakeholders. Key players include Teva Pharmaceutical, Dr. Reddys Laboratories, and Novartis AG, with comprehensive segmentation by drug type, administration route, and distribution channel.
2025-12-28 14:09:36
Voya Investment Management LLC decreased its stake in Teva Pharmaceutical Industries Ltd. by 21.4% during the third quarter, selling 37,902 shares and retaining 139,235 shares valued at $2.81 million. Despite this, other institutional investors have been adding to their positions, and analysts maintain a largely bullish outlook with a consensus "Buy" rating and a target price of $32.88. Insider selling has also occurred, with key executives selling a significant number of shares in December.
